Welcome to The Zitter Group
The Zitter Group helps life sciences and medical product manufacturers work more effectively with managed care companies. Since 1989, we have worked with and for most of the major pharmaceutical, biotech, and medical device companies – and all of the major managed care organizations. We are considered the premier firm in this segment due to the quality of our service and output. But what really sets us apart from the competition is our:
- The largest payer panel research infrastructure, allowing TZG to field quantitative surveys with 100+ payers
- The largest database of detailed health plan prior authorization policies and metrics on PA processes and impact
- The largest syndicated studies focused on payer management of biologic and oncologic therapies, as well as employer and payer practices related to health benefit design
- The only broad-based service tracking the content of account manager visits to payers, including detailed messages
- Simulated, double-blinded P&T committee category reviews that are more realistic and objective than traditional mock P&Ts or advisory boards
Our clients work with us because we offer fresh, new options for managed care marketing. We can help you improve the way you:
- Segment your market
- Apply market analytics and position your products
- Conduct advisory boards and educational symposia
- Communicate your product’s value to the managed care audience
- Allocate scarce marketing resources to the best managed care opportunities
Because we have worked with a number of large managed care organizations as well as pharmacy benefits managers (PBMs), we can help you better understand these organizations.
Why Managed Care?
Third party payers – predominantly managed care organizations – account for over three-quarters of prescriptions in the United States. While other audiences, including physicians and patients, remain critical decision-makers, a product’s success (or failure) can be strongly influenced by the commercial payer market. More importantly, in our experience, most life science companies could be doing more – and thus selling more – within the managed care market.
What’s New
- TZG recently released the Fall 2011 edition of the Managed Care Biologics and Injectables Index, the largest quantitative analysis of specialty management. Learn more.
- TZG recently released the Fall 2011 edition of the Managed Care Benefit Design Index: Emerging Trends in Access, a two arm study with payers and self-insured employers on emerging trends in access. Learn more.
- TZG is currently distributing the Summer 2011 edition of the Managed Care Oncology Index, a semi annual primary market research study on the evolution of oncology management by commercial payers. Learn more.